Original language | English (US) |
---|---|
Pages (from-to) | 281-284 |
Number of pages | 4 |
Journal | Annals of Allergy, Asthma and Immunology |
Volume | 121 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2018 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis : AGREE conference. / participants of AGREE.
In: Annals of Allergy, Asthma and Immunology, Vol. 121, No. 3, 09.2018, p. 281-284.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis
T2 - AGREE conference
AU - participants of AGREE
AU - Spergel, Jonathan M.
AU - Dellon, Evan S.
AU - Liacouras, Chris A.
AU - Hirano, Ikuo
AU - Molina-Infante, Javier
AU - Bredenoord, Albert J.
AU - Furuta, Glenn T.
N1 - Funding Information: Funding Sources: This study was funded by the International Gastrointestinal Eosinophilic Diseases Researchers; the David and Denise Bunning Family; grant U54AI117804 (Consortium of Eosinophilic Gastrointestinal Disease Researchers), which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Disease Research, National Center for Advancing Translational Sciences, and is funded through collaboration of National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, and patient advocacy groups, including American Partnership for Eosinophilic Disorders, Campaign Urging Research for Eosinophilic Disease, and Eosinophilic Family Coalition (Drs. Spergel, Furuta, Liacouras, Dellon and Hirano); and grant K24DK100303 from the National Institutes of Health (Dr. Furuta). Funding Information: Disclosures: Dr Spergel reported working as a consultant for Regeneron, DBV Technology, and Kaleo; receiving grants from DBV Technology, Aimmune Therapeutics, and Food Allergy Research Education; and receiving royalities from UpToDate Dr Dellon reported working as a consultant for Adare, Allakos, Alivio, Banner, Celgene/Receptos, Enumeral, GSK, Regeneron, and Shire; receiving research funding from Adare, Celgene/Receptos, Miraca, Meritage, Nutricia, Regeneron, and Shire; and receiving educational grants from Banner and Holoclara. Dr Liacouras reported working as a consultant for Shire, Adare, Abbott Nutrition, Receptos, and TEVA. Dr Hirano reported working as a consultant for Adare and Allakos. Dr Molina-Infante reported receiving research funding and working as a consultant for Dr. Falk Pharma. Dr Furuta reported being a founder of EnteroTrack, working as a consultant for Shire, and receiving royalties from UpToDate.
PY - 2018/9
Y1 - 2018/9
UR - http://www.scopus.com/inward/record.url?scp=85053165983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053165983&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2018.05.035
DO - 10.1016/j.anai.2018.05.035
M3 - Article
C2 - 30030146
AN - SCOPUS:85053165983
VL - 121
SP - 281
EP - 284
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206
IS - 3
ER -